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Platelets play a critical role in maintaining vascular integrity during inflammation, but little is known about 
the underlying molecular mechanisms. Here we report that platelet immunoreceptor tyrosine activation motif 
(ITAM) signaling, but not GPCR signaling, is critical for the prevention of inflammation-induced hemor-
rhage. To generate mice with partial or complete defects in these signaling pathways, we developed a protocol 
for adoptive transfer of genetically and/or chemically inhibited platelets into thrombocytopenic (TP) mice. 
Unexpectedly, platelets with impaired GPCR signaling, a crucial component of platelet plug formation and 
hemostasis, were indistinguishable from WT platelets in their ability to prevent hemorrhage at sites of inflam-
mation. In contrast, inhibition of GPVI or genetic deletion of Clec2, the only ITAM receptors expressed on 
mouse platelets, significantly reduced the ability of platelets to prevent inflammation-induced hemorrhage. 
Moreover, transfusion of platelets without ITAM receptor function or platelets lacking the adapter protein 
SLP-76 into TP mice had no significant effect on vascular integrity during inflammation. These results indicate 
that the control of vascular integrity is a major function of immune-type receptors in platelets, highlighting a 
potential clinical complication of novel antithrombotic agents directed toward the ITAM signaling pathway.
Introduction
Platelets play an essential role in the prevention of excessive blood 
loss after injury (hemostasis), but can also form occlusive thrombi 
at sites of atherosclerotic plaque rupture (thrombosis) (1). Platelet 
plug formation strongly depends on the soluble agonists throm-
bin, ADP, and thromboxane A2 (TxA2), which induce cellular acti-
vation via GPCRs (1). Thrombin, generated in response to the 
exposure of blood to tissue factor in the damaged vascular wall, is 
crucial in the initiation of thrombus formation. ADP and TxA2 are 
released from activated platelets and provide an important posi-
tive feedback pathway for sustained platelet activation and platelet 
recruitment to the growing thrombus. The importance for throm-
bosis and hemostasis of the various platelet GPCR receptors and 
their agonists is documented by the protection from thrombotic 
complications and the increased bleeding tendency observed in 
patients treated with heparin (which inhibits thrombin), aspi-
rin (which blocks TxA2 generation), and/or clopidogrel bisulfate 
(which inhibits one of the ADP receptors, P2Y12) (2). Consistent-
ly, mice lacking the major platelet receptors for thrombin and/or 
ADP exhibit strong protection from experimental thrombosis and 
markedly prolonged tail bleeding times (3).
The platelet receptor for collagen and laminin, glycoprotein VI 
(GPVI), is also critical for the initiation of thrombus formation at 
sites of vascular injury. GPVI belongs to the Ig superfamily of surface 
receptors and depends on its association with the immuno receptor 
tyrosine activation motif–containing (ITAM-containing) FcR γ 
chain for signaling (4). Mice deficient in GPVI exhibit a mild defect 
in hemostasis and moderate to strong protection from thrombosis 
(5). Patients with impaired GPVI expression/function also show a 
mild bleeding diathesis (6, 7). Inhibitors of GPVI are currently being 
evaluated as novel antiplatelet drugs (2). Platelets also express the 
ITAM receptor C-type lectin–2 (CLEC2), but its role in hemostasis 
and thrombosis is not well understood. Whereas some investigators 
demonstrated impaired thrombus formation in the absence of func-
tional CLEC2 (8, 9), others could not reproduce these findings (10). 
Platelet CLEC2, however, plays a critical role during development. 
Mice lacking CLEC2 (11, 12) or its ligand, podoplanin (13, 14), have 
defective separation of their lymphatic and vascular endothelial cells 
that causes petechia in utero. Similar defects were observed in mice 
deficient in Syk, Src-homology leucocyte protein 76 (SLP-76), and 
PLC-γ2, which are components of the CLEC2 signaling pathway (4).
More recent studies suggested that platelets are also critical for 
other physiological and pathological processes, such as angio-
genesis (15), development (16, 17), immunity (18), viral hepatitis 
(19), arthritis (20), atherosclerosis (21), and sepsis (22). At sites of 
inflammation, platelets support leukocyte extravasation (23), but, 
importantly, they also prevent local hemorrhage. Consequently, 
thrombocytopenia (TP) is associated with inflammation-induced 
hemorrhage (24–26). Interestingly, the ability of platelets to safe-
guard vascular integrity at sites of inflammation is independent 
of their ability to form a platelet plug, as inflammation-induced 
hemorrhage was not observed in mice deficient in the major sur-
face adhesion receptors GPIb-V-IX, integrin αIIbβ3, or P-selectin 
(26, 27). Additional mechanistic studies suggest (a) that the plate-
let support of vascular integrity in inflammation depends on 
intracellular storage granules and release of the vasoactive com-
pounds stored therein (28), and (b) that platelets protect vascular 
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integrity by dampening the inflammatory response (29, 30). How-
ever, no information is available on the agonist receptors or the 
intracellular signaling pathways required for the vessel-stabilizing 
activity of platelets at sites of inflammation.
TP mice have been a very powerful tool for the identification 
of novel platelet functions in health and disease (see above). The 
method most commonly used to render mice TP is based on our 
previous studies on the cytotoxic effects of antibodies directed 
toward major platelet surface receptors (31), which demonstrated 
that antibodies against the glycoprotein Ibα (GPIbα) subunit of 
the GPIb-V-IX receptor complex and the major integrin recep-
tor on platelets, αIIbβ3, cause virtually complete TP in mice (31). 
However, while mice receiving anti-GPIbα antibodies do not show 
any signs of distress, mice receiving anti-αIIbβ3 antibodies develop 
an anaphylaxis-like reaction, with symptoms that include hypo-
thermia and a decrease in hematocrit due to internal bleeding. 
Thus, antibodies against GPIbα have emerged as the most reliable 
method to safely render mice TP for studies on the role of platelets 
in disease. The disadvantage of this method, however, is that the 
antibody remains in circulation and also targets platelets that are 
transfused into the TP mice. Consequently, comprehensive stud-
ies on platelet signaling molecules that are important for vascu-
lar integrity in inflammation would require deletion of multiple 
genes specifically in the megakaryocyte/platelet lineage using the 
loxP/PF4-Cre system (32). The technical difficulties, the costs, 
and the time associated with generation of these mice call for an 
alternative, more efficient method to generate mice with defects in 
multiple platelet signaling molecules.
In this study, we used a novel method to generate mice with plate-
let-specific signaling defects, based on adoptive transfer of platelets 
into TP mice, to study the platelet signaling responses required for 
the maintenance of vascular integrity in inflammation.
Results
Adoptive transfer of WT platelets into TP mice. Studying the role of 
platelet GPCR and ITAM signaling for vascular integrity in inflam-
mation requires a method that allows for the rapid and efficient 
generation of mice with platelet-specific defects in multiple sig-
naling molecules. Thus, we first established a protocol for the 
adoptive transfer of genetically modified and/or inhibitor-treated 
platelets into TP mice. We hypothesized that Tg mice expressing a 
chimeric human IL-4 receptor α/GPIbα (hIL-4Rα/GPIbα) protein 
instead of GPIbα on the platelet surface (33) could be rendered 
TP without side effects by infusion of antibodies against hIL-4Rα. 
Injection of anti–hIL-4Rα antibody led to virtually complete TP, 
but not neutropenia, in the hIL-4Rα/GPIbα–Tg mice (Figure 1A). 
As was the case using antibodies against GPIbα in WT mice (31), 
anti–IL-4R–induced TP in hIL-4Rα/GPIbα–Tg mice was not asso-
ciated with hypothermia (Figure 1B). In contrast, infusion of an 
antibody against αIIbβ3 into hIL-4Rα/GPIbα–Tg mice induced a 
significant drop in platelet count and body temperature within 
30 minutes (Figure 1B). We next tested whether WT platelets 
could be successfully transfused into TP hIL-4R/GPIb–Tg mice. 
Transfusion of 2 × 108, 4 × 108, and 8 × 108 WT platelets into TP 
hIL-4Rα/GPIbα–Tg mice raised the peripheral platelet count to 
18.00% ± 5.76%, 29.50% ± 7.32%, and 56.25% ± 5.81%, respectively, 
of the level in untreated control hIL-4Rα/GPIbα–Tg mice (Figure 
1C). In contrast, WT platelets infused into WT mice that received 
an anti-GPIbα antibody to induce TP were immediately cleared 
from the circulation (Figure 1D). In summary, we demonstrated 
that an anti–hIL-4R antibody can be used to safely deplete circulat-
ing platelets in hIL-4Rα/GPIbα–Tg mice, facilitating the adoptive 
transfer of WT platelets into TP mice.
To test the ability of transfused WT platelets to form thrombi 
at sites of vascular injury, we next studied platelet adhesion to 
endothelium damaged by laser injury (34). In this model, a throm-
bus consisting of platelets and fibrin formed rapidly at the site 
of vascular injury in control WT mice (Figure 2A). We detected 
fibrin, but not platelets, in injured venules of TP hIL-4Rα/GPIbα–
Tg mice (Figure 2A). WT platelets transfused into TP hIL-4Rα/
GPIbα–Tg mice were indistinguishable from endogenous plate-
lets in WT control mice in their ability to adhere to and aggregate 
at sites of vascular injury (Figure 2A). Importantly, transfused 
platelets also prevented a loss of vascular integrity in models of 
immune complex–mediated inflammation in the skin (reverse pas-
sive Arthus [rpA] reaction) and LPS-induced inflammation in the 
Figure 1
Adoptive transfer of WT platelets into TP hIL-4Rα/GPIbα–
Tg mice. (A) TP was induced in hIL-4Rα/GPIbα–Tg mice 
by injection of antibodies against hIL-4R. Peripheral plate-
let and neutrophil counts were determined at the indicated 
time points after injection of anti–hIL-4R antibodies (n = 5). 
Results are expressed as percent of count before antibody 
injection. ***P < 0.001 versus 0 minutes. (B) Body tempera-
ture was measured over time after injection of anti–hIL-4R 
or anti-αIIbβ3 monoclonal antibodies (MoAb) into hIL-4Rα/
GPIbα–Tg mice or injection of anti-GPIbα monoclonal anti-
bodies into WT controls (n = 5 per antibody). **P < 0.01, 
*P < 0.05 versus PBS. (C and D) Peripheral platelet count 
in TP hIL-4Rα/GPIbα–Tg (TP Tg; C) or TP WT (D) mice 
transfused with the indicated amounts of WT platelets (n = 
4). Results are expressed as percent of count before anti-
body injection (“Tg” and “WT” groups).
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lung (Figure 2, B and C). In the rpA reaction, mice were challenged 
by intravenous injection of BSA and intradermal application of 
anti-BSA antibodies, and bleeding at the site of inflammation was 
assessed by quantification of tissue hemoglobin (Hb). Compared 
with unchallenged (0.10 ± 0.008 mg/cm2; data not shown) or 
rpA-challenged (0.25 ± 0.05 mg/cm2) hIL-4Rα/GPIbα–Tg control 
mice, tissue Hb content was significantly increased in TP hIL-4Rα/
GPIbα–Tg mice 4 hours after rPA challenge (1.28 ± 0.08 mg/cm2; 
Figure 2B). Transfusion of 2 × 108, 4 × 108, and 8 × 108 WT plate-
lets into TP hIL-4Rα/GPIbα–Tg mice dose-dependently decreased 
tissue Hb at sites of inflammation (0.76 ± 0.10, 0.47 ± 0.04, and 
0.29 ± 0.03 mg/cm2, respectively). To induce inflammation in the 
lung, mice were challenged by intranasal administration of 7 μg 
LPS, and Hb levels were determined in the lavage fluid 6 hours 
later. Compared with control hIL-4Rα/GPIbα–Tg mice (0.12 ± 
0.02 mg/ml), significantly increased Hb levels were observed in 
the lavage fluid of LPS-challenged TP hIL-4Rα/GPIbα–Tg mice 
(2.77 ± 0.30 mg/ml; Figure 2C). Consistent with our findings in 
the rpA model, transfusion of 8 × 108 WT platelets into TP hIL-
4Rα/GPIbα–Tg mice before LPS challenge completely prevented 
hemorrhage in lungs (0.14 ± 0.05 mg/ml; Figure 2C).
Platelet GPCR signaling and vascular integrity in inflammation. To 
better understand how platelets secure vascular integrity at sites 
of inflammation, we investigated the roles of platelet GPCRs and 
ITAM receptors in this process. We first studied platelet prepara-
tions with defects in GPCR signaling: (a) platelets isolated from 
mice deficient in the thrombin receptor Par4 (35), (b) platelets 
isolated from mice treated with clopidogrel to irreversibly inhibit 
P2Y12, the main receptor for ADP, (c) platelets treated with aspirin 
to irreversibly inhibit cyclooxygenase-dependent TxA2 formation, 
and (d) Par4-deficient platelets treated with both clopidogrel and 
aspirin (referred to herein as Par4–/–/clopidogrel/aspirin plate-
lets). To confirm the lack of GPCR response in these platelets, we 
tested their ability for integrin inside-out activation and α granule 
release in vitro. As shown in Figure 3A, Par4–/–/clopidogrel/aspi-
rin platelets were unresponsive to stimulation with PAR4 recep-
tor–activating peptide (PAR4p) or the combination of the second-
wave mediators ADP and TxA2 (U46619). Both integrin activation 
and α granule release in Par4–/–/clopidogrel/aspirin platelets were 
partially reduced in response to activation with the snake toxin 
convulxin and with podoplanin (Figure 3A), which confirmed that 
full platelet activation via the ITAM receptors GPVI and CLEC2, 
respectively, requires feedback activation by ADP and TxA2 (4). 
Consistent with these in vitro studies, platelets with impaired 
GPCR signaling were markedly impaired in their ability to form 
3-dimensional thrombi at sites of vascular injury (Figure 3B).
Next, all platelet preparations with defects in GPCR signaling 
were tested for their ability to prevent hemorrhage at sites of rPA-
induced inflammation (Figure 4, A and B). 8 × 108 platelets iso-
lated from WT mice, Par4–/– mice, clopidogrel-treated WT mice, 
or clopidogrel-treated Par4–/– mice were incubated in the presence 
or absence of aspirin, washed, and transfused into TP hIL-4Rα/
Figure 2
In vivo function of WT platelets transfused into TP hIL-4Rα/GPIbα–Tg mice. (A) Representative images of cremasteric venules taken 50 seconds 
after laser injury in WT mice, TP hIL-4Rα/GPIbα–Tg mice, and TP hIL-4Rα/GPIbα–Tg mice transfused with 8 × 108 WT platelets. Mice were inject-
ed with Alexa Fluor 488–labeled antibodies against GPIX to label circulating platelets (green) and Alexa Fluor 647–labeled antibodies against 
fibrin (blue). Note the complete lack of platelet accumulation in TP hIL-4Rα/GPIbα–Tg mice. Fibrin generation in the same mice demonstrated 
successful vascular injury. Scale bars: 10 μm. (B) Hb levels in skin lesions 4 hours after rpA challenge in hIL-4Rα/GPIbα–Tg mice and in TP hIL-
4Rα/GPIbα–Tg mice reconstituted or not with the indicated amounts of WT platelets (n = 12 spots per concentration). Representative lesion sites 
are also shown. (C) Hb levels in BAL 6 hours after LPS challenge in hIL-4Rα/GPIbα–Tg mice and in TP hIL-4Rα/GPIbα–Tg mice reconstituted 
or not with 8 × 108 WT platelets (n = 6 per group). Representative images of BAL are also shown. *P < 0.05, **P < 0.01, ***P < 0.001 versus TP 
Tg with no platelet reconstitution, or as indicated by brackets.
research article
4 The Journal of Clinical Investigation   http://www.jci.org
GPIbα–Tg mice before rpA challenge. All platelet transfusions 
significantly increased the peripheral platelet counts in TP hIL-
4Rα/GPIbα–Tg mice to approximately 50% of that in control mice 
(Supplemental Figure 1, A and C). Surprisingly, clopidogrel-inhib-
ited WT platelets, aspirin-inhibited WT platelets, Par4–/– platelets, 
and Par4–/–/clopidogrel/aspirin platelets all reduced hemorrhage 
at sites of rpA-induced inflammation — as assessed by tissue Hb 
levels (0.26 ± 0.03, 0.20 ± 0.02, 0.27 ± 0.04, and 0.21 ± 0.03 mg/cm2, 
respectively) and macroscopic evaluation — to a level comparable 
to that observed in TP hIL-4Rα/GPIbα–Tg mice transfused with 
WT platelets (0.29 ± 0.02 mg/cm2; Figure 4, A and B). These results 
suggested that GPCR signaling in platelets is not critical for main-
taining vascular integrity during inflammation. In support of this 
conclusion, Par4–/–/clopidogrel/aspirin platelets were also indis-
tinguishable from WT platelets in their ability to prevent pul-
monary hemorrhage in TP hIL-4Rα/GPIbα–Tg mice after intra-
nasal administration of LPS (0.15 ± 0.07 and 0.14 ± 0.05 mg/ml 
Hb, respectively; Figure 4, C and D).
Platelet ITAM signaling and vascular integrity in inflammation. While 
the GPCR signaling pathway is important for platelet activation 
by soluble agonists, signaling via ITAM receptors is required 
for platelet activation by components of the ECM and extra-
vascular cells. Mouse platelets express 2 ITAM receptors: GPVI, 
a receptor for collagen and laminin in the ECM, and CLEC2, a 
receptor for podoplanin expressed on extravascular cells (4). To 
study the role of platelet ITAM signaling in the maintenance of 
vascular integrity, we tested 4 different platelet preparations: (a) 
platelets treated in vitro with JAQ1, a blocking monoclonal anti-
body against GPVI (36), (b) platelets isolated from Clec2–/– mice, 
(c) JAQ1-treated Clec2–/– platelets, and (d) platelets isolated from 
mice lacking Slp76, known to be downstream of ITAM signaling 
receptors (37). In vitro, all platelet preparations with defects in 
ITAM signaling showed normal integrin activation and α granule 
release in response to the GPCR agonists PAR4p and ADP plus 
U46619 (Supplemental Figure 2 and Figure 5A). JAQ1-treated WT 
and Clec2–/– platelets were impaired in their responses to the GPVI 
agonist convulxin and the CLEC2 agonist podoplanin, respectively 
(Supplemental Figure 2). As expected, integrin activation and α 
granule release in response to convulxin or podoplanin were abol-
ished in JAQ1-treated Clec2–/– and Slp76–/– platelets (Supplemental 
Figure 2 and Figure 5A). As we observed in platelets with impaired 
GPCR signaling (Figure 3B), Slp76–/– platelets were markedly 
impaired in their ability to form 3-dimensional thrombi in crem-
asteric venules after laser injury (Figure 5B).
Upon transfusion into TP hIL-4Rα/GPIbα–Tg mice, JAQ1-
treated WT platelets only partially restored vascular integrity 
compared with untreated WT platelets at sites of inflammation 
induced by rpA (0.60 ± 0.10 versus 0.29 ± 0.03 mg/cm2 Hb; Fig-
ure 6, A and B) or by LPS (1.07 ± 0.10 versus 0.14 ± 0.05 mg/ml 
Hb; Figure 6, C and D). Platelets isolated from Clec2–/– mice also 
partially reduced hemorrhage in TP hIL-4Rα/GPIbα–Tg mice 
induced by rpA (0.63 ± 0.72 mg/cm2 Hb) and LPS (1.62 ± 0.20 
mg/ml Hb). Transfusion of JAQ1-treated Clec2–/– platelets into 
TP hIL-4Rα/GPIbα–Tg mice had no significant effect on hemor-
rhage induced by rpA (1.06 ± 0.13 mg/cm2 Hb) and LPS (2.42 ± 
0.27 mg/ml Hb), and neither did transfusion of Slp76–/– platelets 
Figure 3
Characterization of platelets with impaired GPCR signaling. (A) WT or Par4–/–/clopidogrel/aspirin (P/C/A) platelets were activated with the indicat-
ed agonists, stained for activated αIIbβ3 and surface P-selectin, and analyzed directly by flow cytometry. Data are representative of 3 independent 
experiments. (B) Representative images of cremasteric venules taken 90 seconds after laser injury in TP hIL-4Rα/GPIbα–Tg mice reconstituted 
with 8 × 108 WT or Par4–/–/clopidogrel/aspirin platelets. Mice were injected with Alexa Fluor 488–labeled antibodies against GPIX to label circulat-
ing platelets (green) and Alexa Fluor 647–labeled antibodies against fibrin (blue). Scale bars: 10 μm.
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(Figure 6, A–D). Peripheral platelet counts were similar in mice 
transfused with the respective platelet preparations (Supplemen-
tal Figure 1, B and D), excluding the possibility that hemorrhage 
at sites of inflammation was the result of impaired survival of 
platelets after adoptive transfer. These results demonstrated that 
the protective effect of platelets in the maintenance of vascular 
integrity during inflammation depends on the 2 ITAM receptors 
GPVI and CLEC2 and the adapter protein SLP-76.
Discussion
Our studies using a novel method to generate mice with multiple 
platelet-specific signaling defects identified platelet ITAM sig-
naling as a critical event in the maintenance of vascular integrity 
at sites of inflammation. Platelets defective in ITAM signaling 
were unable to prevent hemorrhage at sites of immune complex–
induced inflammation in the skin as well as LPS-induced inflam-
mation in the lung. In contrast, platelets defective in GPCR signal-
ing were indistinguishable from WT platelets in their ability to 
support vascular integrity in both models. Our findings provided 
evidence that the platelet signaling response required to prevent 
hemorrhage in inflammation can be generalized for different trig-
gers and vascular beds, although this conclusion will need to be 
confirmed in other models of inflammation.
The central finding of our work was that the platelet ITAM sig-
naling pathway is critical for the maintenance of vascular integ-
rity in inflammation. Mouse platelets express 2 ITAM receptors, 
GPVI and CLEC2. Inhibition of GPVI or deficiency in CLEC2 par-
tially reduced the ability of platelets to maintain vascular integrity 
in immune complex–induced inflammation in the skin or LPS-
induced inflammation in the lung. A defect in both GPVI and 
CLEC2 signaling, or genetic deletion of the downstream adapter 
protein SLP-76, completely abolished the positive effect of plate-
lets on vascular integrity. GPVI signaling is likely activated at sites 
of inflammation by collagen and/or laminin, the 2 physiological 
ligands for GPVI found in the vessel wall (38). More difficult to 
explain, however, is how CLEC2 on platelets is activated in these 
situations. Biochemical and genetic studies have established the 
transmembrane protein podoplanin as the major CLEC2 ligand. 
Podoplanin expression was first documented in glomerular podo-
cytes, lymphatic endothelium, and the brain (39). However, podo-
planin was not found in blood endothelial cells or pericytes, and 
smooth muscle podoplanin was identified in advanced, but not 
early, atherosclerotic lesions (40). Thus, podoplanin is not consti-
tutively expressed in the vessel wall. In LPS-induced inflammation 
in the lung, platelet CLEC2 may engage podoplanin expressed at 
high levels in type I epithelial cells in alveolae (41). However, a 
cellular source for podoplanin has not yet been identified in the 
skin. Alternatively, podoplanin could be “delivered” to sites of 
inflammation by infiltrating macrophages, a recently identified 
source of this molecule (42). Our observations that both GPVI 
and CLEC2 contributed to a similar extent to platelet-dependent 
vascular integrity in the lung and skin are consistent with a tis-
sue-independent source of podoplanin as the trigger of platelet 
CLEC2 signaling. Finally, it is also possible that platelet CLEC2 
receptors respond to an as yet unidentified ligand expressed in 
these tissues or in the vessel wall. Future studies in mice with con-
ditional deletion of podoplanin in various tissues/cell types, such 
as alveolar cells, lymphatic endothelial cells, monocytes/macro-
phages, or smooth muscle cells, will be required to distinguish 
among these possible mechanisms.
Figure 4
Platelet GPCR signaling is not required for the maintenance of vascular integrity in inflammation. (A and B) rpA reaction in skin of TP hIL-4Rα/
GPIbα–Tg mice reconstituted or not (–) with the indicated platelet preparations (8 × 108 platelets/mouse; n = 15–20 spots per group). Clop, 
clopidogrel; ASA, aspirin. (A) Hb levels in skin lesions 4 hours after rpA challenge. Intradermal injection of PBS (without rpA) is also shown. (B) 
Representative images of rpA reaction sites (indicated by dashed outlines and arrows). (C and D) LPS-induced inflammation in lungs of TP hIL-
4Rα/GPIbα–Tg mice reconstituted or not with the indicated platelet preparations (8 × 108 platelets/mouse; n = 5 per group). (C) Hb levels in BAL 
6 hours after LPS challenge. Intradermal injection of PBS (without LPS) is also shown. (D) Representative images of BAL. ***P < 0.001 versus 
no platelet reconstitution.
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Our results also provided evidence that platelet activation via 
soluble agonists, such as thrombin, TxA2, and ADP, is dispensable 
for the contribution of these cells to the maintenance of vascular 
integrity. This is surprising, as all 3 agonists play key roles in the 
ability of platelets to form thrombi at sites of vascular injury (1). 
Furthermore, ADP and TxA2 provide critical feedback signaling 
for platelet activation via ITAM receptors (1). As shown recently, 
however, platelets contribute to vascular integrity in inflamma-
tion by a mechanism that is independent of platelet aggregation 
and hemostasis (26, 27), but likely depends on the release of vaso-
active mediators stored in platelet granules. Activation by ITAM 
receptors may trigger a specific release reaction different from 
that induced by GPCRs. Such agonist-specific differences in the 
released granule content have been described recently, but these 
studies were focused on the different agonists for GPCRs (43).
Finally, our work highlighted similarities between the molecu-
lar mechanisms regulating vascular integrity in inflammation and 
those facilitating the separation of blood and lymphatic vessels 
during development. As shown by various groups, lymphatic vas-
cular development during embryogenesis is dependent on platelet 
activation via the CLEC2/SLP-76 axis (11, 12). Blood-filled lym-
phatics were also observed in adult mice transplanted with bone 
marrow from Clec2–/– or Slp76–/– mice (11). In contrast, no such 
defects have been described for mice lacking components of the 
GPCR signaling machinery or for mice deficient in key receptors 
for platelet adhesion and aggregation. It is important to note, 
however, that defects in lymphatic vascular development have not 
been described for mice lacking GPVI, which suggests that the 
molecular mechanisms regulating vascular development and vas-
cular integrity in the adult differ, at least with regard to triggering 
platelet activation.
Critical to our studies was the development of an adoptive trans-
fer system for platelets into TP mice. Here, selective depletion of 
circulating platelets was achieved in Tg mice with antibodies that 
recognize hIL-4R, a heterologous antigen expressed on circulating 
platelets in these mice. With the use of this technique, we were 
able to rapidly deplete virtually all circulating platelets in hIL-
4Rα/GPIbα–Tg mice and replace them with platelets defective in 
all major GPCR or ITAM receptors. Importantly, this antibody-
mediated depletion of platelets did not affect neutrophils or other 
blood cells (data not shown). In comparison, peripheral platelet 
counts in mice lacking the thrombopoietin receptor c-Mpl, a key 
regulator of megakaryocytopoiesis, are only reduced by approxi-
mately 90% compared with controls (44). The remaining platelets 
are fully functional, and c-mpl–/– mice do not bleed. Furthermore, 
c-Mpl deficiency also affects other hematopoietic progenitor cells 
and thus does not represent a platelet-specific model. Mice lacking 
the transcription factor p47 NF-E2 (45, 46) have near-complete TP 
due to a defect on thrombopoiesis, which leads to excessive hem-
orrhage and perinatal lethality. In addition, p47 NF-E2 knockout 
mice show several red blood cell defects. Finally, TP induced by 
chemotherapeutic agents, such as 1,4-butanediol dimethanesul-
fonate (Busulfan; ref. 47), is accompanied by leukopenia, and thus 
cannot be used for studying inflammation in mice.
In summary, we here described the comprehensive analysis of the 
platelet signaling response required to maintain vascular integ-
Figure 5
Impaired platelet ITAM signaling and thrombosis in Slp76–/– mice. (A) Washed platelets from WT or Slp76–/– mice were activated with the indicated 
agonists, stained for activated αIIbβ3 and surface P-selectin, and analyzed by flow cytometry. Data are representative of 3 independent experi-
ments. (B) Representative images of cremasteric venules taken 90 seconds after laser injury in TP hIL-4Rα/GPIbα–Tg mice reconstituted with 8 
× 108 WT or Slp76–/– platelets. Mice were injected with Alexa Fluor 488–labeled antibodies against GPIX to label circulating platelets (green) and 
Alexa Fluor 647–labeled antibodies against fibrin (blue). Scale bars: 10 μm.
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rity in inflammation. By generating mice with multiple platelet-
specific signaling defects, we demonstrated that vascular integrity 
in inflammation depended on both ITAM receptors, GPVI and 
CLEC2, as well as the adapter protein SLP-76. In contrast, signaling 
via the major GPCRs was dispensable for this response. Our studies 
highlight potential complications associated with novel antiplate-
let drugs targeting the ITAM signaling pathway, which may lead to 
blood-lymph mixing or to bleeding at sites of inflammation.
Methods
Animals. 6- to 8-week-old C57BL/6 WT mice were purchased from Jackson 
laboratory. Par4–/– mice (35) and hIL-4Rα/GPIbα–Tg mice (33) were bred 
and housed in our animal facility. Where indicated, WT and Par4–/– mice 
were treated with clopidogrel 24 and 3 hours before the experiment at a 
dosage of 75 mg/kg body weight (34). Clec2–/– and Slp76fl/fl;PF4-Cre chime-
ric (Slp76–/–) mice (11, 37) were generated by transplant of the respective 
bone marrow into WT mice lethally irradiated with 2 doses of 6.5 Gy 4 
hours apart (13 Gy total) using a Cs137 irradiator (J.L. Shepherd).
Reagents and antibodies. Low–molecular weight enoxaparin sodium 
(Lovenox) and clopidogrel (Plavix) were purchased from Sanofi-Aventis, 
and heparin-coated capillaries were purchased from VWR. Aspirin was 
purchased from Bayer. Hb, BSA, prostacyclin (PGI2), LPS, ADP, red blood 
cell lysis buffer, and formic acid were purchased from Sigma-Aldrich. The 
following antibodies were used: anti-GPIbα, GPIX, GPVI, and JON/A-PE 
(Emfret Analytics); recombinant mouse podoplanin/Fc chimera protein 
and anti–hIL-4R (clone 25463; R&D Systems); anti-αIIbβ3, Ly6G, and FITC-
conjugated anti–P-selectin (BD Biosciences); anti-BSA (MP Biomedical). 
Alexa Fluor 647–labeled antibodies against fibrin were a gift from R. 
Camire (Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, 
USA). Convulxin was provided by K.J. Clemetson (Theodor Kocher Insti-
tute, Bern, Switzerland), and PAR4p was purchased from Advanced Chem-
tech. U46619 was purchased from Cayman Chemical.
Platelet depletion. TP was induced in WT or hIL-4Rα/GPIbα–Tg mice by 
retro-orbital injection of antibodies against GPIbα and hIL-4R, respective-
ly (2.5 μg/g body weight). Peripheral platelet and neutrophil counts were 
assessed by flow cytometry 4 hours after antibody injection (see below).
Platelet transfusion. Blood was drawn into heparinized tubes from the 
retro-orbital plexus of sedated mice (7.7 μl/g body weight). Platelet-rich 
plasma (PRP) was obtained by centrifugation at 100 g for 5 minutes. PRP 
was centrifuged at 700 g in the presence of PGI2 (2 μg/ml) for 5 minutes 
at room temperature. After 1 washing step, pelleted platelets were resus-
pended in modified Tyrode’s buffer (137 mM NaCl, 0.3 mM Na2HPO4, 
2 mM KCl, 12 mM NaHCO3, 5 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid, 5 mM glucose, pH 7.3). Platelets from several donor 
mice were pooled, and the platelet count was adjusted to 1 × 109, 2 × 109, 
or 4 × 109 platelets/ml. BSA was added to purified platelets to yield a final 
BSA concentration of 150 μg/g body weight in mice. Recipient mice were 
injected with 200 μl washed platelets and BSA.
Flow cytometry. For determination of endogenous and transfused platelet 
counts, diluted whole blood was stained with antibodies against GPIbα (phy-
coerythrin labeled; 2 μg/ml) and GPIX (Alexa Fluor 488 labeled; 2 μg/ml), 
and counts were assessed by flow cytometry (Accuri C6; BD Biosciences). To 
document the selective depletion of hIL-4Rα/GPIb–Tg platelets by anti–hIL-
4R antibodies, we transfused WT platelets into hIL-4Rα/GPIbα–Tg mice, fol-
lowed by injection of anti–hIL-4R antibodies (Supplemental Figure 3).
For determination of peripheral neutrophil counts, 50 μl heparinized 
whole blood was lysed in red cell lysis buffer for 10 minutes at room tem-
perature. The lysed cells were centrifuged at 250 g, and the supernatant 
Figure 6
Platelet ITAM signaling is critical for the maintenance of vascular integrity during inflammation. (A and B) Hemorrhage in skin lesions of TP 
hIL-4Rα/GPIbα–Tg mice reconstituted or not with the indicated platelet preparations (8 × 108 platelets/mouse), with or without treatment with 
JAQ1 antibody (n = 15–20 spots per group). (A) Hb levels 4 hours after rpA challenge. Intradermal injection of PBS (without rpA) is also shown. 
(B) Representative images of lesions (dashed outlines and arrowheads). (C and D) LPS-induced inflammation in lungs of TP hIL-4Rα/GPIbα–
Tg mice reconstituted or not with the indicated platelet preparations (8 × 108 platelets/mouse), with or without treatment with JAQ1 antibody 
(n = 3–5 per group). (C) Hb levels in BAL after LPS challenge. Intradermal injection of PBS (without LPS) is also shown. (D) Representative 
images of BAL. **P < 0.01, ***P < 0.001 versus WT platelets; #P < 0.001 versus no platelet reconstitution.
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